

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/003,635	11/02/2001	Joseph C. Salamone	P02866	8360 .	
75	90 03/14/2003				
Bausch & Lomb Inc.			EXAMINER		
One Bausch & Lomb Place Rochester, NY 14604-2701			PENG, KUO LIANG		
			ART UNIT	PAPER NUMBER	
			1712		
			DATE MAILED: 03/14/2003)	

Please find below and/or attached an Office communication concerning this application or proceeding.

					C2 (
· .	2	Application No.	-	Applicant(s)				
		10/003,635		SALAMONE ET AL				
	Office Action Summary	Examiner	-	Art Unit				
4		Kuo-Liang Peng		1712				
	The MAILING DATE of this communication app ars on th c ver sh et with the correspondence address Period for R ply							
A SHO THE N - Exter after - If the - If NO - Failui - Any re	ORTENED STATUTORY PERIOD FOR REPL' MAILING DATE OF THIS COMMUNICATION. sisions of time may be available under the provisions of 37 CFR 1.1: SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, how y within the statutory mir will apply and will expire c, cause the application t	ever, may a reply be tim nimum of thirty (30) days SIX (6) MONTHS from to become ABANDONED	ely filed will be considered timely. he mailing date of this con 0 (35 U.S.C. § 133).	nmunication.			
1)🖂	Responsive to communication(s) filed on 2/7/	<u>′03 Response</u> .						
2a)[This action is FINAL . 2b)⊠ Th	is action is non-f	nal.					
3)□ Dispositi	Since this application is in condition for allowed closed in accordance with the practice under on of Claims				merits is			
4)🖂	Claim(s) 1-28 is/are pending in the application	۱.		,				
•	4a) Of the above claim(s) is/are withdraw	wn from consider	ation.					
5)	Claim(s) is/are allowed.				•			
6)⊠	Claim(s) 7-13 and 19-28 is/are rejected.							
7)⊠	Claim(s) 7-13 and 19-28 is/are objected to.							
8)□	Claim(s) are subject to restriction and/o	r election require	ment.		•			
Applicati	on Papers							
9) 🔲 🗀	The specification is objected to by the Examine	r.						
10) 🔲 7	The drawing(s) filed on is/are: a)☐ accep	pted or b)⊡ object	ed to by the Exan	niner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)[1	The proposed drawing correction filed on			ved by the Examiner	:			
If approved, corrected drawings are required in reply to this Office action.								
	The oath or declaration is objected to by the Ex	aminer.						
	nder 35 U.S.C. §§ 119 and 120							
	Acknowledgment is made of a claim for foreign	n priority under 35	5 U.S.C. § 119(a)	-(d) or (f).				
a)[☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	 Copies of the certified copies of the prior application from the International But ee the attached detailed Office action for a list 	reau (PCT Rule 1	17.2(a)).		tage			
14) 🗌 A	cknowledgment is made of a claim for domestic	c priority under 3	5 U.S.C. § 119(e) (to a provisional a	application).			
	☐ The translation of the foreign language procknowledgment is made of a claim for domesti							
Attachment —	(s)							
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>4</u>	4)		(PTO-413) Paper No(s) atent Application (PTO-				
S Patent and Tra	1. 100	<u> </u>						



Art Unit: 1712

DETAILED ACTION

1. Applicant's election of the invention of Group III in Paper No. 6 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

The requirement is still deemed proper and is therefore made FINAL.

Groups I-II and IV-V, Claims 1-6 and 14-18, are withdrawn for further consideration.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 7-13 and 19-28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 7-13 and 19-28 of copending Application No. 10/000,136. Although the conflicting claims are not identical, they are not patentably distinct from each other because of the following reasons: When z is 0 in the siloxysilane monomers set forth in the copending Application, Claims 7-13 and 19-28 of the



Art Unit: 1712

copending Application obviously disclose Claims 7-13 and 19-28, respectively, of the present Application wherein y is 1 in the siloxysilane monomers.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

4. The following are Examiner's suggestions/questions:

In Claim 27, before "methacrylate", should there be -- cycloalkyl --?

Claim Objections

5. Claims 7-13 and 19-28 are objected to because of the following informalities:

It is noted that the limitation of Claim 1 should be included in Claims 7-10 and 19-26. It is further noted that in Claim 1 (page, line 2), should "alkyl", "alkyloxy", "aryl" and "aryloxy" be -- alkylene--, -- alkyleneoxy --, -- arylene -- and -- aryleneoxy --, respectively?

Appropriate correction is required.

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 7. Claims 7-13 and 19-28 are rejected under 35 U.S.C. 102(b) as being anticipated by Toyashima (US 4,954,586).



Art Unit: 1712

With respect to Claim 7, Toyashima discloses a polymeric composition comprising tris(trimethylsiloxy)silylpropyl (meth)acrylate (i.e., reads on "one or more monomers" wherein y is 0, and R¹ is methyl, X is propylene and R is (meth)acryloxy) (col. 11, line 65-66) and components (A) to (D) (col. 3, line 14 to col. 4, line 35).

With respect to Claims 8 and 11, Toyashima further teaches the use of methyl methacrylate (col. 7, lines 12-13) or N,N-dimethyl acrylamide (col. 11, line 47).

With respect to Claims 9 and 12, Toyashima further teaches the use of 2-ethylhexyl methacrylate (col. 7, line 18).

With respect to Claims 10 and 13, Toyashima further teaches the use of N,N-dimethyl acrylate (col. 11, line 47) or N-methyl acrylamide (col. 11, line 45).

With respect to Claims 19-22 and 27, Toyashima further teaches the use of cycloalkyl (meth)acrylate such as cyclopentyl (meth)acrylate or cyclohexyl (meth)acrylate (col. 7, lines 12 and 21-22).

With respect to Claims 23-26 and 28, Toyashima further teaches the use of a crosslinking agent such as ethylene glycol di(meth)acrylate, triethylene glycol di(meth)acrylate, etc. (col. 10, line 44 to col. 11, line 6).

8. Claims 7-12, 23-26 and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Gaylord (US 3,808,178).

With respect to Claim 7, Gaylord discloses a polymeric composition produced through the polymerization of a polysiloxanylalkyl ester monomer described in col. 1, line 61 to col. 2, line 9, wherein X and Y is a group of Z, and A is C₁-C₅ alkyl group and phenyl groups. It is



Art Unit: 1712

noted that the phenyl substituents on the polysiloxanyl monomer enhance the refractive index of the polymeric composition (col. 5, lines 28-30).

With respect to Claims 8-9 and 11-12, Gaylord further teaches the use of an alkanol ester of (meth)acrylic acid such as methyl methacrylate, 2-ethylhexyl (meth)acrylate, etc. (col. 1, lines 29-44 and col. 3, lines 59-60).

With respect to Claim 10, Gaylord further teaches the use of a hydrophilic monomer (col. 4, lines 50-62).

With respect to Claims 23-26 and 28, Gaylord further teaches the use of a crosslinking agent such as ethylene glycol dimethacrylate, butylene glycol dimethacrylate, neopentyl glycol diacrylate, etc. (col. 5, lines 6-14).

- 9. The references cited in the specification US 4,327,203, US 4,355,147, US 5,270,418, US 5,217,491 and US 5,326,506 have been considered.
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kuo-Liang Peng whose telephone number is (703) 306-5550. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Dawson, can be reached on (703) 308-2340. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9310.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0661.

Page 6

Application/Control Number: 10/003,635

Art Unit: 1712

Kuo-Liang Peng

March 3, 2003

Knokinker